Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Free Report) has received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among […]
Operator: Thank you for standing by. Welcome to the Merck & Co. Q4 Sales and Earnings Conference Call. [Operator Instructions] This call is being recorded.
Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average […]
Merck & Co., Inc. (NYSE:MRK) Q4 2023 Earnings Call Transcript February 1, 2024 Merck & Co., Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. Welcome to the Merck & Co. Q4 Sales and Earnings […]